Stemsynergy Therapeutics,

StemSynergy Therapeutics, Inc. (SSTI) is a biotechnology company focused on discovering drugs that target biomolecules and cellular processes fundamental to cancer. We target the cancer stem/initiating cell (CSC) populations, with the overall aim of eliminating tumor growth. We have two patents awarded and one patent pending for breakthrough technologies in modulating cancer stem cell pathways, such as those driven by Wnt, Notch, and Sonic Hedgehog (Shh) signaling. With a multi-pronged scientific approach and a number of agents targeting these pathways, SSTI is well positioned to address critical unmet needs in cancer treatment.